Funding profile · Pharmaceutical distribution and embedded finance

Remedial Health

$17.4 million disclosed across three rounds in eighteen months, then nothing announced for more than three years. The only United States securities filing tied to the company is an $80,000 side vehicle, and it was filed five months before the Series A was made public.

$17.4MTotal disclosed, pre-seed through Series A (2022 to 2023)
$13.4MEquity portion; the remaining $4.0M is debt
$80,000The only Form D on record, a Gaingels vehicle (Feb 2023)
11Investors in that vehicle, average about $7,273

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2022 Y Combinator Not disclosed Y Combinator YC data
Feb 2022 Pre-seed $1.0M Co-led by Global Ventures and Ventures Platform; Ingressive Capital, Voltron Capital, Opeyemi Awoyemi’s Angel Syndicate Fund, Olugbenga Agboola, Victor Asemota Independent
Sep 2022 Seed, equity $4.4M Led by Global Ventures; Tencent, Y Combinator, Cathexis Ventures, Lightspeed Venture Partners Scout Fund, Ventures Platform, Alumni Ventures, True Capital Management; angels Guillaume Luccisano and Christopher Golda Independent
Feb 2023 SPV: Gaingels Remedial Health LLC $80,000 11 investors; managed by Gaingels Management LLC Form D
Aug 2023 Series A, equity and debt $12.0M total: $8.0M equity, $4.0M debt Equity co-led by QED Investors and Ventures Platform, with Y Combinator, Tencent and Gaingels. Debt led by an unnamed consortium of local and international financial institutions Independent
Since Aug 2023 No round announced None None Not found
Total Disclosed capital $17.4M Of which $13.4M equity Independent

What the filings show

Gaingels Remedial Health LLC · Form D · filed Feb 14, 2023

First sale
Feb 7, 2023
Type
Vermont limited liability company formed 2023, single-company vehicle
Offered
$80,000 equity
Sold
$80,000 · $0 remaining
Investors
11, all accredited · average about $7,273 · minimum accepted $1,000
Exemption
Rule 506(b)
Commissions
$0 sales commissions, $0 finders fees
Related persons
David Beatty, executive officer, manager of Gaingels Management LLC, which manages the issuer
Filing
SEC EDGAR, CIK 0001965233

Reading the filings

  1. The paper landed five months before the press release.The vehicle recorded its first sale on February 7, 2023 and filed on February 14. The Series A was announced on July 31 and August 1, 2023. Either the round had an early close that was never described publicly, or Gaingels came in on a bridge between the September 2022 seed and the Series A. Reporting says only that Gaingels invested “after participating in previous rounds,” yet Gaingels appears in no published pre-seed or seed investor list.
  2. The cheques in that vehicle are retail-sized.$80,000 across 11 investors is about $7,273 each, against a stated $1,000 minimum. That is a syndicate of individuals, not an institution taking a position. It is a rounding error next to the $12 million headline and tells you nothing about the round’s terms.
  3. The company itself files nothing.Remedial Health is Nigerian and has no Form D of its own. Form D covers only Regulation D offerings in the United States, so the absence is expected rather than suspicious. The effect is that the $17.4 million rests on press reports and investor posts, and no offering amount, share class, valuation or investor count can be checked against a primary source.
  4. A third of the headline is debt, and no lender is named.The $12 million splits $8 million equity and $4 million debt. Every outlet repeats one phrase for the debt, a consortium of local and international financial institutions, and none names a member. No development finance institution has disclosed an exposure. For a lender, the cost and tenor of its own funding matters most, and it is absent.
  5. The equity story is one lead compounding.Ventures Platform invested at pre-seed, seed and Series A, and called this its first Series A lead. Global Ventures led the first two rounds and does not appear in the Series A announcement. QED Investors entered at Series A, its third African investment after Moniepoint and FlapKap, and framed the thesis as embedded finance rather than distribution.

Commercial signals

Signal Detail Source type
Regulatory No NAFDAC registration, wholesale licence or premises licence in the company’s name found in public records to Sep 24, 2026. Not found
Customers 7,500 hospitals, pharmacies and PPMVs across all 36 Nigerian states, and 300 million packs sold, for full year 2023. Not independently counted. Company-stated
Suppliers More than 300 manufacturers and more than 8,000 products (2023). Named: GSK, Pfizer, AstraZeneca, Orange Drugs, Emzor, Fidson Healthcare. No manufacturer has confirmed publicly. Company-stated
Credit book 97.5 per cent repayment reported in Sep 2022. Terms: 14 days for pharmacies, 30 for hospitals, 60 for government institutions. No audited loss rate published. Company-stated
Profitability The company told Techpoint Africa it became profitable in December 2022. No accounts have been filed publicly or independently verified. Company-stated
Market share The CEO put it at about 10 per cent in August 2023. Competitors in the same segment include DrugStoc, Lifestores Healthcare and mPharma. Independent

What to watch

  • Any Series B, or an extension of the debt facility, and whether a development finance institution appears in it.
  • The named lenders behind the 2023 debt tranche, which remain unidentified three years on.
  • A new Form D from any vehicle formed around the company, which would date the next round before its announcement, as the Gaingels filing did.
  • A published NAFDAC licence for the distribution entity, the credential a provenance business is selling.
  • Any audited or third party count of customers, volumes or credit losses.

The Remedial Health story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Curebase: Shared investor: Gaingels. A clinical trial company that turned drive-through testing lines into research sites, then closed its services arm and became a software vendor
  • Parallel Bio: Shared investor: Gaingels. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them
  • Arintra: Shared investor: Gaingels. Software that reads a finished patient chart and pushes billing codes straight into the claim, with no coder in between
  • Ochre Bio: Shared investor: Gaingels. An Oxford company that designs RNA drugs and tests them in whole human donor livers kept alive on machines

Sources

  1. Public recordForm D, Gaingels Remedial Health LLC, CIK 0001965233SEC EDGAR · Feb 14, 2023
  2. IndependentNigeria’s Remedial Health gets QED backing in $12M roundTechCrunch, Annie Njanja · Jul 31, 2023
  3. IndependentRemedial Health raises $12 million in series A roundTechCabal, Faith Omoniyi · Aug 1, 2023
  4. IndependentRemedial Health raises a $12m Series ATechpoint Africa, Victoria Fakiya · Aug 1, 2023
  5. IndependentNigeria’s YC-backed Remedial Health raises $4.4M seed fundingTechCrunch, Annie Njanja · Sep 20, 2022
  6. IndependentRemedial Health raises $4.4 million seed roundTechCabal, Muktar Oladunmade · Sep 20, 2022
  7. IndependentYC-backed Remedial Health raises $1 million pre-seed to digitize pharmacies in NigeriaTechCrunch, Annie Njanja · Feb 14, 2022
  8. IndependentNigeria’s Remedial Health unveils new app to power operations for neighbourhood pharmaciesDisrupt Africa, Tom Jackson · Apr 10, 2024
  9. Public recordCurbing Substandard, Falsified (SFS) And Counterfeit MedicinesNAFDAC, Director General statement
  10. InvestorA Milestone Investment: Remedial Health Series A FundingVentures Platform · 2023
  11. CompanyY Combinator company page, Winter 2022 batchY Combinator · accessed Sep 24, 2026

Compiled from SEC and other public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Remedial Health is a Nigerian company and files no Form D of its own, so the round sizes here rest on press reports and investor statements rather than primary filings. Healthcare Venture Capital Fund holds no position in Remedial Health. This page is not an offer to sell or a recommendation to buy any security.